ZyVersa Therapeutics annual operating expenses
2021
2022
2022
2023
2024
2025
ZyVersa Therapeutics Operating Expenses Growth & History (ZVSA)
ZyVersa Therapeutics's operating expenses was $25.5M for fiscal 2025.
View full ZyVersa Therapeutics company overviewZyVersa Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.5M | $16.4M | +179.01% |
| 2024 | 2024-12-31 | $9.1M | −$98.6M | −91.52% |
| 2023 | 2023-12-31 | $107.8M | — | — |
| 2022 | 2022-12-31 | $13.0M | $12.8M | +5431.19% |
| 2022 | 2022-12-12 | $13.0M | $12.8M | +5431.19% |
| 2021 | 2021-12-31 | $235,267 | — | — |
ZyVersa Therapeutics quarterly operating expenses
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $1.3M | −$839,873 | −39.16% |
| Q4 2025 | 2025-12-31 | $551,857 | −$734,742 | −57.11% |
| Q3 2025 | 2025-09-30 | $20.8M | $18.5M | +814.34% |
| Q2 2025 | 2025-06-30 | $2.0M | −$709,846 | −25.78% |
| Q1 2025 | 2025-03-31 | $2.1M | −$682,065 | −24.13% |
| Q4 2024 | 2024-12-31 | $1.3M | −$12.6M | −90.77% |
| Q3 2024 | 2024-09-30 | $2.3M | −$633,057 | −21.81% |
| Q2 2024 | 2024-06-30 | $2.8M | −$83.6M | −96.81% |
| Q1 2024 | 2024-03-31 | $2.8M | −$1.8M | −38.45% |
| Q4 2023 | 2023-12-31 | $13.9M | $3.2M | +29.89% |
| Q3 2023 | 2023-09-30 | $2.9M | $1.9M | +194.51% |
| Q2 2023 | 2023-06-30 | $86.3M | $85.8M | +17208.20% |
| Q1 2023 | 2023-03-31 | $4.6M | $3.8M | +473.26% |
| Q4 2022 | 2022-12-12 | $10.7M | — | — |
| Q3 2022 | 2022-09-30 | $985,605 | $985,431 | +566339.66% |
| Q2 2022 | 2022-06-30 | $498,752 | $497,963 | +63113.18% |
| Q1 2022 | 2022-03-31 | $801,048 | — | — |
| Q3 2021 | 2021-09-30 | $174 | — | — |
| Q2 2021 | 2021-06-30 | $789 | — | — |
ZyVersa Therapeutics operating expenses trends
Between the periods ended 2021-12-31 and 2025-12-31, ZyVersa Therapeutics's operating expenses increased from $235,267 to $25.5M, a change of $25.3M. The latest reported quarter, Q1 2026, shows $1.3M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ZyVersa Therapeutics source filings ↗